2,3-Dimethoxy-5-nitro-6-(2-nitrovinyl)pyridine | 882033-32-1

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: 2,3-Dimethoxy-5-nitro-6-(2-nitrovinyl)pyridine
• 英文别名: 2,3-dimethoxy-5-nitro-6-(2-nitroethenyl)pyridine
• CAS: 882033-32-1
• 化学式: C₉H₉N₃O₆
• 分子量: 255.187
• InChiKey: ZYXNZEUGSDJSGT-UHFFFAOYSA-N

物化性质

• 沸点：
  444.4±45.0 °C(Predicted)
• 密度：
  1.419±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  123
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2,3-Dimethoxy-5-nitro-6-(2-nitrovinyl)pyridine 在 4-二甲氨基吡啶 、 正丁基锂 、 三丁基氯化锡 、 溴 、 silica gel 、 铁粉 、 溶剂黄146 、 三乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 生成 tert-butyl 3-[4-chloro-5-fluoro-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-5,6-dimethoxypyrrolo[3,2-b]pyridine-1-carboxylate
  参考文献：
  名称：

  Design of Potent IGF1-R Inhibitors Related to Bis-azaindoles

  摘要：

  From an azaindole lead, identified in high throughput screen, a series of potent bis‐azaindole inhibitors of IGF1‐R have been synthesized using rational drug design and SAR based on a in silico binding mode hypothesis. Although the resulting compounds produced the expected improved potency, the model was not validated by the co‐crystallization experiments with IGF1‐R.

  DOI：

  10.1111/j.1747-0285.2010.00991.x
• 作为产物：
  描述：

  2-溴-6-碘-3-甲氧基吡啶 在 正丁基锂 、 copper(II) nitrate trihydrate 、 sodium acetate 、 乙酸酐 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 2,3-Dimethoxy-5-nitro-6-(2-nitrovinyl)pyridine
  参考文献：
  名称：

  Design of Potent IGF1-R Inhibitors Related to Bis-azaindoles

  摘要：

  From an azaindole lead, identified in high throughput screen, a series of potent bis‐azaindole inhibitors of IGF1‐R have been synthesized using rational drug design and SAR based on a in silico binding mode hypothesis. Although the resulting compounds produced the expected improved potency, the model was not validated by the co‐crystallization experiments with IGF1‐R.

  DOI：

  10.1111/j.1747-0285.2010.00991.x

文献信息

• Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors
  申请人：NEMECEK Conception

  公开号：US20080045561A1

  公开（公告）日：2008-02-21

  Disclosed are compounds of formula (I): wherein R1, R2, R3, R4, and R5 have the meanings given in the description, and to salts thereof, pharmaceutical compositions comprising said compounds and the use thereof as protein kinase inhibitors.

  本发明涉及化合物（I）的公式，其中R1、R2、R3、R4和R5的含义如说明书中所述，以及其盐、包含该化合物的制药组合物以及其作为蛋白激酶抑制剂的用途。
• Bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors
  申请人：Aventis Pharma S.A.

  公开号：US07786114B2

  公开（公告）日：2010-08-31

  Compounds of formula (I): wherein R1, R2, R3, R4, and R5 have the meanings given in the description, and to salts thereof, pharmaceutical compositions comprising said compounds and the use thereof as protein kinase inhibitors.

  式(I)的化合物：其中R1、R2、R3、R4和R5具有说明中给出的含义，以及其盐，包括该化合物的制药组合物及其作为蛋白激酶抑制剂的用途。
• NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS
  申请人：NEMECEK Conception

  公开号：US20100256141A1

  公开（公告）日：2010-10-07

  Disclosed are compounds of formula (I): wherein R1, R2, R3, R4, and R5 have the meanings given in the description, and to salts thereof, pharmaceutical compositions comprising said compounds and the use thereof as protein kinase inhibitors.

  本发明涉及化合物的公式（I）：其中R1，R2，R3，R4和R5具有描述中给出的含义，以及其盐，包含所述化合物的制药组合物以及其作为蛋白激酶抑制剂的用途。
• Design of Potent IGF1-R Inhibitors Related to Bis-azaindoles
  作者：Conception Nemecek、William A. Metz、Sylvie Wentzler、Fa-Xiang Ding、Corinne Venot、Catherine Souaille、Anne Dagallier、Sébastien Maignan、Jean-Pierre Guilloteau、François Bernard、Alain Henry、Sandrine Grapinet、Dominique Lesuisse

  DOI：10.1111/j.1747-0285.2010.00991.x

  日期：——

  From an azaindole lead, identified in high throughput screen, a series of potent bis‐azaindole inhibitors of IGF1‐R have been synthesized using rational drug design and SAR based on a in silico binding mode hypothesis. Although the resulting compounds produced the expected improved potency, the model was not validated by the co‐crystallization experiments with IGF1‐R.